Manage your pharmacy inventory

Deep knowledge on
small-molecule drugs and
the global patents
covering them

Find generic entry opportunities

Drug patents …
… from Kazakhstan to Kalamazoo

Anticipate generic drug launch

Project your formulary budget

Make Better Decisions

Identify first generic entrants
Uncover prior art in expired and abandoned patents
Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Generated: September 26, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 016267

« Back to Dashboard

NDA 016267 describes DESFERAL, which is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. Additional details are available on the DESFERAL profile page.

The generic ingredient in DESFERAL is deferoxamine mesylate. There are seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the deferoxamine mesylate profile page.

Summary for NDA: 016267

Tradename:	1
Applicant:	1
Ingredient:	1
Patents:	0
Formulation / Manufacturing:	see details

Pharmacology for NDA: 016267

Mechanism of Action	Iron Chelating Activity

Suppliers and Packaging for NDA: 016267

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
DESFERAL	deferoxamine mesylate	INJECTABLE;INJECTION	016267	NDA	Novartis Pharmaceuticals Corporation	0078-0467	0078-0467-91	4 VIAL in 1 CARTON (0078-0467-91) > 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL (0078-0467-61)

Summary for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INJECTION			Strength	500MG/VIAL
Approval Date:	Approved Prior to Jan 1, 1982	TE:	AP	RLD:	Yes

Summary for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INJECTION			Strength	2GM/VIAL
Approval Date:	May 25, 2000	TE:	AP	RLD:	Yes

Expired Orange Book Patents for NDA: 016267

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	DESFERAL	deferoxamine mesylate	INJECTABLE;INJECTION	016267-001	Approved Prior to Jan 1, 1982	► Subscribe	► Subscribe

This preview shows a limited data set Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Complete Access Available with Subscription

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.